151751-Najiba-Chargi

23 Introduction 15. Bernier J, Domenge C, Ozsahin M, et al. Postoperative Irradiation with or without Concomitant Chemotherapy for Locally Advanced Head and Neck Cancer. N Engl J Med . 2004;350(19):1945-1952. doi:10.1056/ NEJMoa032641 16. Guan J, Li Q, Zhang Y, et al. A meta-anal - ysis comparing cisplatin-based to carbo- platin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN). Oncotarget . 2016;7(6):7110-7119. doi:10.18632/onco - target.6858 17. Bonner JA, Harari PM, Giralt J, et al. Radio - therapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med . 2006;354(6):567-578. doi:10.1056/ NEJMoa053422 18. Mehanna H, Robinson M, Hartley A, et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-posi- tive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial. Lancet . 2019;393(10166):51-60. doi:10.1016/S0140-6736(18)32752-1 19. Gillison ML, Trotti AM, Harris J, et al. Ra - diotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyn- geal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferior- ity trial. Lancet . 2019;393(10166):40-50. doi:10.1016/S0140-6736(18)32779-X 20. Gebre-Medhin M, Brun E, Engström P, et al. ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer. J Clin Oncol . 2020;39(1):JCO.20.02072. doi:10.1200/ jco.20.02072 21. Chow LQM, Haddad R, Gupta S, et al. An - titumor activity of pembrolizumab in bio- marker-unselected patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol . 2016;34(32):3838-3845. doi:10.1200/ JCO.2016.68.1478 22. Braakhuis BJM, Brakenhoff RH, Leemans CR. Treatment choice for locally advanced head and neck cancers on the basis of risk factors: biological risk factors. Educ B 37th ESMO Congr Vienna, Austria, 28 Sept – 2 Oct 2012 . 2012;23:x173-x177. doi:10.1093/ annonc/mds299 23. Lydiatt WM, Patel SG, O’Sullivan B, et al. Head and neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin . 2017;67(2):122-137. doi:10.3322/caac.21389 24. Sinha P, Kallogjeri D, Gay H, et al. High met - astatic node number, not extracapsular spread or N-classification is a node-relat- ed prognosticator in transorally-resected, neck-dissected p16-positive oropharynx cancer. Oral Oncol . 2015;51(5):514-520. doi:10.1016/j.oraloncology.2015.02.098 25. De Almeida JR, Li R, Magnuson JS, et al. Oncologic outcomes after transoral ro - botic surgery a multi-institutional study. In: JAMA Otolaryngology - Head and Neck Surgery . Vol 141. American Medical Associ - ation; 2015:1043-1051. doi:10.1001/jamao - to.2015.1508 26. Budach V, Tinhofer I. Novel Prognostic Clin- ical Factors and Biomarkers for Outcome Prediction in Head and Neck Cancer: A Sys- tematic Review . Vol 20.; 2019. www.thelan - cet.com/oncology. Accessed December 19, 2020. 27. Prado CM, Cushen SJ, Orsso CE, Ryan AM. Sarcopenia and cachexia in the era of obe- sity: clinical and nutritional impact. Proc Nutr Soc . 2016;75(2):188-198. doi:10.1017/ S0029665115004279 1